Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1

British Journal of Pharmacology

Volumn 169, Issue 7, 2013, Pages 1525-1536

  Korhonen, Riku ^a   Hömmö, Tuija ^a   Keränen, Tiina ^a   Laavola, Mirka ^a   Hämäläinen, Mari ^a   Vuolteenaho, Katriina ^a   Lehtimäki, Lauri ^a,b   Kankaanranta, Hannu ^a,c   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

DUSP1; MAPK; MKP 1; PDE inhibitors; PDE4; TNF

Indexed keywords

8 BROMO CYCLIC AMP; CARRAGEENAN; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHODIESTERASE IV; RNA; ROLIPRAM; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CELL LINE; CELL LYSATE; CELL STRAIN J774; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MOUSE; NONHUMAN; PAW INFLAMMATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; WILD TYPE;

DUSP1; MAPK; MKP-1; PDE INHIBITORS; PDE4; TNF;

ANIMALS; CARRAGEENAN; CELL LINE; DUAL SPECIFICITY PHOSPHATASE 1; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880276188     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12189     Document Type: Article

References (57)

1. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, et al. (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 1883-1889.
2. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, et al. (2004). Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173: 7531-7538.
3. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al. (2004). Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287: L332-L343.
4. Bender AT, Beavo JA, (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
5. Boutros T, Chevet E, Metrakos P, (2008). Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60: 261-310.
6. Brion L, Maloberti PM, Gomez NV, Poderoso C, Gorostizaga AB, Mori Sequeiros Garcia MM, et al. (2011). MAPK phosphatase-1 (MKP-1) expression is up-regulated by hCG/cAMP and modulates steroidogenesis in MA-10 Leydig cells. Endocrinology 152: 2665-2677.
7. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. (2006). Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 103: 2274-2279.
8. Chong J, Poole P, Leung B, Black PN, (2011). Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (5): CD002309.
9. Crilly A, Robertson SE, Reilly JH, Gracie JA, Lai WQ, Leung BP, et al. (2011). Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Ann Rheum Dis 70: 1130-1137.
10. Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, et al. (2009). Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology 83: 275-286.
11. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R, (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13: 925-931.
12. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A, (1997). In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 121: 221-231.
13. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, Cote J, Duong M, Killian KJ, et al. (2011). Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 12: 140.
14. Hämäläinen M, Korhonen R, Moilanen E, (2009). Calcineurin inhibitors down-regulate iNOS expression by destabilizing mRNA. Int Immunopharmacol 9: 159-167.
15. Houslay MD, (2010). Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100.
16. Houslay MD, Adams DR, (2003). PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18.
17. Houslay MD, Schafer P, Zhang KY, (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
18. Huang G, Wang Y, Shi L, Kanneganti T, Chi H, (2011). Signaling by the phosphatase MKP-1 in dendritic cells imprints distinct effector and regulatory T cell fates. Immunity 35: 45-58.
19. Ikemura T, Schwarze J, Makela M, Kanehiro A, Joetham A, Ohmori K, et al. (2000). Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther 294: 701-706.
20. Jin SL, Conti M, (2002). Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99: 7628-7633.
21. Jin SL, Lan L, Zoudilova M, Conti M, (2005). Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175: 1523-1531.
22. Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, et al. (2010). Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 126: 1252-1259.e12.
23. Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama A, et al. (2001). Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 163: 173-184.
24. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC, (2001). Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20: 7108-7116.
25. Kelly JJ, Barnes PJ, Giembycz MA, (1996). Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. Biochem J 318: 425-436.
26. Keravis T, Lugnier C, (2012). Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165: 1288-1305.
27. Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y, (2011). ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. Int Immunopharmacol 11: 732-739.
28. Korhonen R, Kankaanranta H, Lahti A, Lähde M, Knowles RG, Moilanen E, (2001). Bi-directional effects of the elevation of intracellular calcium on the expression of inducible nitric oxide synthase in J774 macrophages exposed to low and to high concentrations of endotoxin. Biochem J 354: 351-358.
29. Korhonen R, Turpeinen T, Taimi V, Nieminen R, Goulas A, Moilanen E, (2011). Attenuation of the acute inflammatory response by dual specificity phosphatase 1 by inhibition of p38 MAP kinase. Mol Immunol 48: 2059-2068.
30. Korhonen R, Huotari N, Hömmö T, Leppänen T, Moilanen E, (2012). The expression of interleukin-12 is increased by MAP kinase phosphatase-1 through a mechanism related to interferon regulatory factor 1. Mol Immunol 51: 219-226.
31. Kwak SP, Hakes DJ, Martell KJ, Dixon JE, (1994). Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene. J Biol Chem 269: 3596-3604.
32. Lee J, Komatsu K, Lee BC, Lim JH, Jono H, Xu H, et al. (2012). Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. J Biol Chem 287: 22799-22811.
33. Li F, Zhang M, Hussain F, Triantaphyllopoulos K, Clark AR, Bhavsar PK, et al. (2011). Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 37: 933-942.
34. McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, et al. (2010). Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 12: R107.
35. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
36. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, Knowles RG, (2011). In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 337: 137-144.
37. Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E, (2010). Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum 62: 1650-1659.
38. Page C, Spina D, (2012). Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12: 275-286.
39. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. (2012). Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380: 738-746.
40. Patterson KI, Brummer T, O'Brien PM, Daly RJ, (2009). Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418: 475-489.
41. Plotnikov A, Zehorai E, Procaccia S, Seger R, (2011). The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 1813: 1619-1633.
42. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, et al. (1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159: 6253-6259.
43. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T, (2006). Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176: 1899-1907.
44. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. (2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159: 842-855.
45. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. (2012). Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64: 3156-3167.
46. Shepherd MC, Baillie GS, Stirling DI, Houslay MD, (2004). Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142: 339-351.
47. Shipp LE, Lee JV, Yu C, Pufall M, Zhang P, Scott DK, et al. (2010). Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS ONE 5: e13754.
48. Spina D, (2008). PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315.
49. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. (2000). Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59: 347-356.
50. Turpeinen T, Nieminen R, Moilanen E, Korhonen R, (2010). Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells. J Pharmacol Exp Ther 333: 310-318.
51. Vattakuzhi Y, Abraham SM, Freidin A, Clark AR, Horwood NJ, (2012). Dual-specificity phosphatase-1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis. Arthritis Rheum 62: 2201-2210.
52. Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin SL, (1995). Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 47: 1164-1171.
53. Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM, (1997). Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun 234: 320-324.
54. Yamaki K, Li X, Hossain MA, Alam AH, Taneda S, Yanagisawa R, et al. (2007). Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice. Immunol Invest 36: 131-145.
55. Yu H, Li Q, Herbert B, Zinna R, Martin K, Junior CR, et al. (2010). Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss. Gene Ther 18: 344-353.
56. Zhang J, Wang Q, Zhu N, Yu M, Shen B, Xiang J, et al. (2008). Cyclic AMP inhibits JNK activation by CREB-mediated induction of c-FLIP(L) and MKP-1, thereby antagonizing UV-induced apoptosis. Cell Death Differ 15: 1654-1662.
57. Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, et al. (2006). MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 203: 131-140.